Loading…
Loading…
Axis Capital (AXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.
PEMBROKE, Bermuda, July 06, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2026 on Tuesday, July 28, 2026 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Matthew Kirk, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 29, 2026 at 8:30 a.m.
Axis Capital (AXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AXIS Capital's specialty insurance strength, premium growth and underwriting profitability support growth, while currency exposure and economic uncertainty remain concerns.
PEMBROKE, Bermuda, June 15, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) today announced that it has appointed Pradip Patiath to the Company's Board of Directors. Effective June 15, 2026, Mr. Patiath will join the Board, where he will serve on its Risk and Human Capital and Compensation Committees.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for AXS and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.